^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® HRD Focus Panel

    Company:
    Amoy Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [HRD-Ovarian Cancer-olaparib]

    Source:
    ASCO 2022
    Test:

    AmoyDx® HRD Focus Panel

    Title:
    The correlation of homologous recombination deficiency status with and Olaparib efficacy in Chinese ovarian cancer patients.
    Published date:
    05/26/2022
    Excerpt:
    A significant PFS benefit was seen in HRD-positive patients compared with HRD-negative ones (P = 0.0017) or in the first-line maintenance treated population (P = 0.0068).
    DOI:
    10.1200/JCO.2022.40.16_suppl.e17556
    Evidence Level:
    Sensitive: C3 – Early Trials

    [HRD-Ovarian Cancer-niraparib]

    Source:
    J Ovarian Res
    Test:

    AmoyDx® HRD Focus Panel

    Title:
    The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
    Published date:
    05/17/2021
    Excerpt:
    Twenty-two patients all received niraparib at a bolus of 200 mg/d. Fifty percent of patients with high-grade serous ovarian cancer are HRD-positive....two patients achieved partial response (PR) and one patient achieved stable disease (SD), yielding objective response rate (ORR) of 33.3%...
    DOI:
    10.1186/s13048-021-00803-2